Free Trial
NASDAQ:NYXH

Nyxoah (NYXH) Stock Price, News & Analysis

Nyxoah logo
$9.50
-0.09 (-0.94%)
(As of 10/31/2024 ET)

About Nyxoah Stock (NASDAQ:NYXH)

Key Stats

Today's Range
$9.39
$9.67
50-Day Range
$7.33
$9.74
52-Week Range
$4.00
$20.00
Volume
9,846 shs
Average Volume
50,149 shs
Market Capitalization
$236.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Buy

Company Overview

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
60th Percentile Overall Score

NYXH MarketRank™: 

Nyxoah scored higher than 60% of companies evaluated by MarketBeat, and ranked 444th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nyxoah has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Nyxoah has only been the subject of 3 research reports in the past 90 days.

  • Read more about Nyxoah's stock forecast and price target.
  • Earnings Growth

    Earnings for Nyxoah are expected to grow in the coming year, from ($1.86) to ($1.57) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Nyxoah is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Nyxoah is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Nyxoah has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Nyxoah's valuation and earnings.
  • Percentage of Shares Shorted

    0.49% of the float of Nyxoah has been sold short.
  • Short Interest Ratio / Days to Cover

    Nyxoah has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nyxoah has recently decreased by 12.85%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nyxoah does not currently pay a dividend.

  • Dividend Growth

    Nyxoah does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.49% of the float of Nyxoah has been sold short.
  • Short Interest Ratio / Days to Cover

    Nyxoah has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nyxoah has recently decreased by 12.85%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Nyxoah has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Nyxoah this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Nyxoah to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Nyxoah insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    17.11% of the stock of Nyxoah is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Nyxoah's insider trading history.
Receive NYXH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter.

NYXH Stock News Headlines

Publication relating to transparency notifications
Nyxoah to Announce Q3 2024 Financial Results
This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Publication relating to transparency notifications
Publication relating to transparency notifications
See More Headlines

NYXH Stock Analysis - Frequently Asked Questions

Nyxoah's stock was trading at $4.64 at the beginning of 2024. Since then, NYXH stock has increased by 104.7% and is now trading at $9.50.
View the best growth stocks for 2024 here
.

Nyxoah S.A. (NASDAQ:NYXH) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.46) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.01. The business had revenue of $0.83 million for the quarter, compared to analysts' expectations of $1.93 million. Nyxoah had a negative trailing twelve-month return on equity of 42.00% and a negative net margin of 908.32%.

Nyxoah (NYXH) raised $83 million in an initial public offering (IPO) on Friday, July 2nd 2021. The company issued 2,760,000 shares at $30.00 per share.

Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Nyxoah investors own include PayPal (PYPL), Confluent (CFLT), Datadog (DDOG), Baidu (BIDU), Arcadia Biosciences (RKDA), SEA (SE) and ZoomInfo Technologies (ZI).

Company Calendar

Last Earnings
8/06/2024
Today
10/31/2024
Next Earnings (Confirmed)
11/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NYXH
Employees
146
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$20.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+75.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-46,770,000.00
Net Margins
-908.32%
Pretax Margin
-950.70%

Debt

Sales & Book Value

Annual Sales
$4.79 million
Book Value
$5.08 per share

Miscellaneous

Free Float
N/A
Market Cap
$241.17 million
Optionable
Not Optionable
Beta
1.45
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:NYXH) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners